SLC5A2 and hydrops fetalis: Suggested mechanisms by which SGLT2 inhibitors lower the risk of mortality in patients with HF include their anti-inflammatory properties, support of antioxidant defense systems, and reduced cardiac remodeling or fibrosis (34–36).